Central nervous system infections in transplantation
Tóm tắt
Central nervous system (CNS) infections are a rare but serious complication of transplantation. An appropriate diagnostic workup should be streamlined with stratification of infection risk by length and degree of immune suppression, lesion localization, and timing. Polymerase chain reaction has high sensitivity and specificity for rapid identification of viral infections and should be used when available. Early diagnosis is imperative, and biopsy should be pursued if a diagnosis is not readily obtained with noninvasive testing. Treatment is pathogen specific. Combination antifungal therapy should be considered for cerebral aspergillosis. Zygomycetes and related invasive fungi require surgical resection and high-dose antifungal therapy. Viral meningoencephalitis therapy should be continued until resolution of clinical signs and symptoms, and viral clearance is verified with repeat cerebrospinal fluid analysis. Cytomegalovirus encephalitis requires ongoing maintenance therapy until clearance of viremia or antigenemia. Bacterial meningitis is uncommon in transplantation and should be treated with 21 days of antibiotics. CNS bacterial abscesses, including nocardiosis, should be surgically drained if feasible and treated until resolution of clinical and radiographic evidence of infection.
Tài liệu tham khảo
National Marrow Donor Program: 2004 Statistics. http://www.marrow.org. Accessed December 15, 2005.
Scientific Registry of Transplant Recipients 2004 Annual Report. http://www.ustransplant.org. Accessed December 15, 2005.
Graus F, Saiz A, Sierra J, et al.: Neurologic complications of autologous and allogenic bone marrow transplantation in patients with leukemia: a comparative study. Neurology 1996, 46:1004–1009.
Saiz A, Graus F: Neurological complications of hematopoietic cell transplantation. Semin Neurol 2004, 24:427–434. This review describes neurologic complications encountered at each stage of transplantation.
Sostak P, Padovan CS, Yousry TA, et al.: Prospective evaluation of neurological complications after allogenic bone marrow transplantation. Neurology 2003, 60:842–848. Seventy-one patients were followed prospectively for an average of 14 months after HCT. Forty-six developed neurologic complications, eight of which were infections.
Gallardo D, Ferra C, Berlanga JJ, et al.: Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 18:1135–1139.
Singh N, Husain S: Infections of the central nervous system in transplant recipients. Transpl Infect Dis 2000, 2:101–111. This excellent review addresses CNS infections in SOT and HCT recipients.
Roos KL: Central nervous system infections after hemopoietic stem cell or solid organ transplantation. In Transplant Infections, edn 2. Edited by Bowden RA, Ljungman P, Paya CV. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:730. This chapter describes common CNS infections and their treatment in SOT and HCT.
Fishman JA, Rubin RH: Infection in organ-transplant recipients. N Engl J Med 1998, 338:1741–1751.
Patel R, Paya CV: Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997, 10:86–124.
Zerr DM, Gooley TA, Yeung L, et al.: Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 33:763–771. This retrospective analysis looked at characteristics of patients developing HHV6 encephalitis.
Kimberlin DW, Whitley RJ: Human herpesvirus-6: neurologic implications of a newly-described viral pathogen. J Neurovirol 1998, 4:474–485.
Singh N, Paterson DL: Encephalitis caused by human herpesvirus-6 in transplant recipients: relevance of a novel neurotropic virus. Transplantation 2000, 69:2474–2479.
Caserta MT, Mock DJ, Dewhurst S: Human herpesvirus 6. Clin Infect Dis 2001, 33:829–833.
BonhamCA, Dominguez EA, Fukui MB, et al.: Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1988, 66:1596–1604. This prospective study of 1730 liver transplant recipients over 4 years found that 60 had a CNS mass lesion. Eleven of 60 were infections (all fungal). Eight of 11 fungal infections had concurrent pulmonary disease.
Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909–917. This retrospective study details risk factors and prognosis related to mold infections in HCT recipients.
Nucci M: Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003, 16:607–612.
Husain S, Alexander BD, Munoz P, et al.: Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003, 37:221–229.
Spellberg B, Edwards JJr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556–569.
Brown J: Zygomycosis: an emerging fungal infection. Am J Health Syst Pharm 2005, 62:2593–2596.
Kishi Y, Miyakoshi S, Kami M, et al.: Early central nervous system complications after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:561–568.
Junghanss C, Boeckh M, Carter RA, et al.: Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002, 99:1978–1985.
Junghanss C, Marr KA, Carter RA, et al.: Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002, 8:512–520.
Junghanss C, Marr KA: Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002, 15:347–353.
Robertson KB, Barron MA, Nieto Y: West Nile virus infection in bone marrow transplant patients. Bone Marrow Transplant 2004, 34:823–824.
Roos KL: West Nile encephalitis and myelitis. Curr Opin Neurol 2004, 17:343–346.
Wadei H, Alangaden GJ, Sillix DH, et al.: West Nile virus encephalitis: an emerging disease in renal transplant recipients. Clin Transplant 2004, 18:753–758.
Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep 2000, 49:1–28.
Marr K: Combination antifungal therapy: where are we now, and where are we going? Oncology (Williston Park) 2004, 18:24–29.
MarrKA, Boeckh M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797–802. This small retrospective study found that patients on combination antifungal therapy had better survival than those on monotherapy.
Ito Y, Kimura H, Yabuta Y, et al.: Exacerbation of herpes simplex encephalitis after successful treatment with acyclovir. Clin Infect Dis 2000, 30:185–187.
Steiner I, Budka H, Chaudhuri A, et al.: Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol 2005, 12:331–343.
Kennedy PG: Viral encephalitis: causes, differential diagnosis, and management. J Neurol Neurosurg Psychiatry 2004, 75(Suppl 1):i10-i15. This review details the considerations in diagnosing and treating viral encephalitis.
2005 Drug Topics Red Book. Edited by Fleming T. Montvale, NJ: Medical Economics Co.; 2005:864.
Dupont B: Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002, 49(Suppl 1):31–36.
Groll AH, Giri N, Petraitis V, et al.: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274–282.
Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al.: Voriconazole. Clin Ther 2003, 25:1321–1381.
de LastoursV, Lefort A, Zappa M, et al.: Two cases of cerebral aspergillosis successfully treated with voriconazole. Eur J Clin Microbiol Infect Dis 2003, 22:297–299.
Marbello L, Nosari A, Carrafiello G, et al.: Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient. Haematologica 2003, 88:ECR05.
Schwartz S, Thiel E: Update on the treatment of cerebral aspergillosis. Ann Hematol 2004, 83(Suppl 1):S42-S44. This brief report describes the CSF and brain penetration of antifungals and reviews the literature on treatment of cerebral aspergillosis.
Clemons KV, Espiritu M, Parmar R, Stevens DA: Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005, 49:4867–4875.
Julin JE, van Burik JH, Krivit W, et al.: Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Transplant Infect Dis 2002, 4:201–206.
Nichols WG, Boeckh M: Recent advances in the therapy and prevention of CMV infection. J Clin Virol 2000, 16:25–40.
Kayacan SM, Turkmen A, Alis H, et al.: Successful therapy combined with surgery for severe post-transplant nocardiosis. J Nephrol 2001, 14:304–306.
Dubey A, Patwardhan RV, Sampth S, et al.: Intracranial fungal granuloma: analysis of 40 patients and review of the literature. Surg Neurol 2005, 63:254–260.
Sundaram C, Mahadevan A, Laxmi V, et al.: Cerebral zygomycosis. Mycoses 2005, 48:396–407.
Revankar SG, Sutton DA, Rinaldi MG: Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004, 38:206–216.
Al-Abdely HM: Management of rare fungal infections. Curr Opin Infect Dis 2004, 17:527–532.
Torres HA, Hachem RY, Chemaly RF, et al.: Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005, 5:775–785.
Pitisuttithum P, Negroni R, Graybill JR, et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56:745–755.
Segal BH, Barnhart LA, Anderson VL, et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005, 40:1684–1688.